Evolving Nursing Research Priorities: A Unified Vision for Advancing the Nursing Profession.

The American Nurses Association Enterprise (ANA Enterprise) Research Advisory Council plays a vital role in bringing nursing voices together and shaping the dynamic landscape of nursing research. Historically, its priorities have revolved around 4 pivotal research priorities: advancing research capacity, promoting interprofessional collaboration, enhancing data structures and governance, and propelling practice-based nursing research. In a remarkable transition, the 2024 Research Priorities of the ANA Enterprise Research Advisory Council align with the vision and strategic goals of the ANA Enterprise. The Council now places emphasis on the intersection of the research priorities with 5 key areas crucial for "elevating the profession of nursing globally": workforce development; advancing nurse well-being practices; deepening understanding of diversity, equity, inclusion, and belonging; expanding scope of practice; and measuring the value of nursing. This approach provides clear guidance for nursing research efforts, demonstrating a dedicated effort to harmonize the diverse voices within the nursing community. The objective is to shape a future where nursing research not only serves to inform practice but also enhances the overall value and impact of the nursing profession globally.

A Path Forward in Nurse-Led Research: Turning Priorities Into Actionable Items.

To raise nurses' voices and promote nurse-led research, the American Nurses Credentialing Center's Research Council 2022 Research Priorities included disseminating a research agenda for practice-based research, promoting interprofessional research, and encouraging equitable and inclusive participation on research teams. Expressions of nurses from around the world, however, described how organizational constraints and financial barriers are real challenges that nurse researchers must face, along with forming interdisciplinary teams to work with human subjects. Entities doing research seem to have a heavy focus on academic research where clinical bedside nurses feel separated from nursing research. Including all frontline nurses in research is a must; therefore, nurses' voices are loud and clear when asking for global efforts to be reoriented toward nurse-led, practice-based research and to turn the research priorities into easy-to-carry-forward and achievable actionable items.

Establishing a Pathway to Excellence® Research Agenda: A Delphi Study to Identify Research Priorities for Evaluating Positive Practice Environments.

OBJECTIVE: The aim of this study was to develop research priorities for positive practice environments identified by Pathway to Excellence® (Pathway) leaders and appraisers. BACKGROUND: Identifying research priorities achieves 2 goals: 1) advancing research agendas that impact improving practice environments, and nurse and patient outcomes; and 2) informing nursing leaders, researchers, and funders of potential research projects to conduct and support. METHODS: Research topics related to the 6 Pathway standards were developed and then rated for importance through 3 rounds of a Delphi survey by leaders at Pathway-designated organizations and Pathway appraisers. RESULTS: Twenty research priorities were identified from the initial 54 research topics. The top 2 priorities were building and maintaining shared governance participation (91.9%) and nurse participation in performance improvement and evidence-based practice activities (90.7%). CONCLUSIONS: Establishing a Pathway research agenda will guide nursing leadership, researchers, and funders in selecting impactful research priorities to help bolster positive practice environments that engage and empower nurses.

The 2022 ANCC Institute for Credentialing Research and Quality Management Priorities: A Path Forward in Nurse-Led Research.

ABSTRACT: It is imperative that we listen to our nation's nurses, who have a unique vantage point from their clinical environments. Clinical research nurses have greatly contributed to studying the delivery of care over the years; however, since 2020, COVID-19 has brought unprecedented changes within the nursing profession. Each wave of the pandemic has created a worrisome landscape where nurse researchers face multiple challenges in implementing and funding practice-based nursing-led research projects. To raise nurses' voices and promote nurse-led research, the American Nurses Credentialing Center (ANCC) Research Council 2022 Research Priorities include the dissemination of a research agenda for practice-based research, promoting interprofessional research, and encouraging equitable and inclusive participation on research teams.

BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.

PURPOSE: CXCR4 has been identified as a prognostic marker for acute myeloid leukemia (AML) and other malignancies. We describe the development and characterization of a fully human antibody to CXCR4 and its application for therapy of AML, non-Hodgkin lymphoma (NHL), chronic lymphoid leukemia (CLL), and multiple myeloma. EXPERIMENTAL DESIGN: Human transgenic mice were immunized with CXCR4-expressing cells, and antibodies reactive with CXCR4 were analyzed for apoptosis induction and ability to interfere with CXCL12-induced migration and calcium flux. In vivo efficacy was determined in multiple AML, NHL, and multiple myeloma xenograft tumors in severe combined immunodeficient mice. RESULTS: BMS-936564/MDX-1338 is a fully human IgG(4) monoclonal antibody that specifically recognizes human CXCR4. In vitro studies show that MDX-1338 binds to CXCR4-expressing cells with low nanomolar affinity, blocks CXCL12 binding to CXCR4-expressing cells, and inhibits CXCL12-induced migration and calcium flux with low nanomolar EC(50) values. When given as monotherapy, MDX-1338 exhibits antitumor activity in established tumors including AML, NHL, and multiple myeloma xenograft models. In addition, we show that MDX-1338 induced apoptosis on a panel of cell lines and propose that antibody-induced apoptosis is one of the mechanisms of tumor growth inhibition. CONCLUSIONS: BMS-936564/MDX-1338 is a potent CXCR4 antagonist which is efficacious as monotherapy in tumor-bearing mice and is currently in phase I for the treatment of relapsed/refractory AML, NHL, CLL, and multiple myeloma.